Pharma Mar (PHMMF) Stock Price, News & Analysis

Company Overview

PharmaMar is a Spanish biopharmaceutical company focused on discovering, developing and commercializing medicines for oncology. Its research draws on marine organisms as a source of compounds with potential anticancer properties.

The company’s oncology portfolio includes Yondelis (trabectedin), used to treat certain soft-tissue sarcomas and ovarian cancer, and Zepzelca (lurbinectedin), used to treat small-cell lung cancer in certain markets. PharmaMar also conducts research into new cancer treatments and works with commercial partners to bring its medicines to patients in different geographies.

Founded in 1986, PharmaMar is headquartered in Spain. Its chief executive officer and chairman, José María Fernández Sousa-Faro, has led the company since its early years.

Key Stats

• Today's Range: $75.05 to $75.05
• 50-Day Range: $70.70 to $94.60
• 52-Week Range: $70.70 to $106.48
• Volume: N/A
• Average Volume: 56 shs
• Market Capitalization: $1.35 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

Pharma Mar Stock Analysis - MarketRank™

Pharma Mar scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Buy

Consensus Rating

Pharma Mar has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Pharma Mar has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Pharma Mar are expected to grow in the coming year, from ($1.04) to $2.14 per share.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.13% of the float of Pharma Mar has been sold short.

Short Interest Ratio / Days to Cover

Pharma Mar has a short interest ratio ("days to cover") of 240.21, which indicates bearish sentiment.

Change versus previous month

Short interest in Pharma Mar has recently decreased by 0.09%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pharma Mar does not currently pay a dividend.

Dividend Growth

Pharma Mar does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pharma Mar insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.88% of the stock of Pharma Mar is held by insiders.

Percentage Held by Institutions

Pharma Mar has minimal institutional ownership at this time.

Company Calendar

• Today: 11/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:PHMMF
• Previous Symbol: NASDAQ:PHMMF
• CIK: N/A
• Web: www.pharmamar.com
• Phone: (491) 846-6000
• Fax: 34-91-846-6001
• Employees: 505
• Year Founded: 1986

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $250.42 million
• Price / Sales: 5.39
• Cash Flow: $0.41 per share
• Price / Cash Flow: 181.20
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 18,000,000
• Free Float: 17,662,000
• Market Cap: $1.35 billion
• Optionable: Not Optionable
• Beta: 0.87